Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04GZS
|
|||
| Former ID |
DIB013022
|
|||
| Drug Name |
Tempol
|
|||
| Synonyms |
MTS-01; Tempol (hypertension); Tempol (hypertension), Cary; Tempol (gel formulation, hair loss), Mitos
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Spinal cord injury [ICD-11: ND51.2] | Phase 2 | [1] | |
| Company |
Georgetown University; Mitos Pharmaceuticals Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C9H18NO2
|
|||
| Canonical SMILES |
CC1(CC(CC(N1[O])(C)C)O)C
|
|||
| InChI |
1S/C9H18NO2/c1-8(2)5-7(11)6-9(3,4)10(8)12/h7,11H,5-6H2,1-4H3
|
|||
| InChIKey |
UZFMOKQJFYMBGY-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 2226-96-2
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Superoxide dismutase Cu-Zn (SOD Cu-Zn) | Target Info | Modulator | [2], [3] |
| BioCyc | Reactive oxygen species degradation | |||
| KEGG Pathway | Peroxisome | |||
| Amyotrophic lateral sclerosis (ALS) | ||||
| Huntington's disease | ||||
| Prion diseases | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Pathwhiz Pathway | Degradation of Superoxides | |||
| Pathway Interaction Database | Validated nuclear estrogen receptor alpha network | |||
| FOXA1 transcription factor network | ||||
| Reactome | Platelet degranulation | |||
| Detoxification of Reactive Oxygen Species | ||||
| WikiPathways | Oxidative Stress | |||
| Copper homeostasis | ||||
| Detoxification of Reactive Oxygen Species | ||||
| Nifedipine Activity | ||||
| Amyotrophic lateral sclerosis (ALS) | ||||
| Dopamine metabolism | ||||
| AGE/RAGE pathway | ||||
| Folate Metabolism | ||||
| Vitamin B12 Metabolism | ||||
| Selenium Micronutrient Network | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00801086) Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain. U.S. National Institutes of Health. | |||
| REF 2 | The superoxide dismutase mimetic, tempol, reduces the bioavailability of nitric oxide and does not alter L-NAME-induced hypertension in rats. Basic Clin Pharmacol Toxicol. 2005 Jul;97(1):29-34. | |||
| REF 3 | Effect of the addition of two superoxide dismutase analogues (Tempo and Tempol) to alpaca semen extender for cryopreservation. Theriogenology. 2013 Mar 15;79(5):842-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.